{"id":831326,"date":"2025-03-30T11:33:03","date_gmt":"2025-03-30T15:33:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/"},"modified":"2025-03-30T11:33:03","modified_gmt":"2025-03-30T15:33:03","slug":"reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/","title":{"rendered":"Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CUPERTINO, Calif., March  30, 2025  (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place March 29 to April 2, 2025 in Chicago, Illinois, U.S.<\/p>\n<p align=\"justify\">\n        <strong>Details for the oral presentation can be found below:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Title:\u00a0<\/strong>Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants<\/p>\n<p align=\"justify\">\n        <strong>Session:\u00a0<\/strong>Pharmaceutical Pipeline<\/p>\n<p align=\"justify\">\n        <strong>Date and Time:\u00a0<\/strong>Sunday, March 30<sup>th<\/sup> from 10:30 AM \u2013 12:00 PM ET CST<\/p>\n<p align=\"justify\">\n        <strong>Presenter: Dr. Laxminarayan Bhat, Founder &amp; CEO, Reviva Pharmaceuticals<\/strong>\n      <\/p>\n<p align=\"justify\">Abstracts and additional details can be found at the SIRS 2025\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L7WLsPNlRO3Yhnh86B6w-qA9-MOOJZ_a0yu3PoxaW2Ngju2d6gtxHAEqiOLgH1y0ZOkfLEBM1fhoA8Kx4XQf6o893kiOPFaP6N8NswaRdu04ezlKJYmDU6JpsvyGqKbQVeFZtWs3smlhU1U0O0BasQ==\" rel=\"nofollow\" target=\"_blank\"><u>website<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Reviva\u00a0<\/strong><br \/>\n        <br \/>Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva&#8217;s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva&#8217;s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>Reviva Pharmaceuticals Holdings, Inc.<br \/>Laxminarayan Bhat, PhD<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1nEkHi0v1_Lso7hbkpp4xQe-FJkWhDJSjc4w-Qq8tITZik8dULO7L88psnxiVOLJSh8Qk5-hbyWsEs0a_goFlUbyJmd1UR11so1vQUfUbWw=\" rel=\"nofollow\" target=\"_blank\"><u>www.revivapharma.com<\/u><\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>LifeSci Advisors, LLC<br \/>Bruce Mackle<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QDvKmrBP7a2zFoGBWoDKt6s0mMTC-3-_dUhz5f5Oy5S3ldG1GQMVSFJm1CdvP5-QcFDo52Myvay6L0rmSVJUTVOYvuAM_UOi8JTQmfREg6T18wt7rxCQiPR1kb8GF407\" rel=\"nofollow\" target=\"_blank\"><u>bmackle@lifesciadvisors.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjQxOCM2ODM4NDcwIzUwMDA3NTM4MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzMwMTQ5ZjktYjVjNi00YzU0LTkxN2QtOTEwNmVmNDYzZDU3LTUwMDA3NTM4MS0yMDI1LTAzLTMwLWVu\/tiny\/Reviva-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place March 29 to April 2, 2025 in Chicago, Illinois, U.S. Details for the oral presentation can be found below: Title:\u00a0Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants Session:\u00a0Pharmaceutical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-831326","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place March 29 to April 2, 2025 in Chicago, Illinois, U.S. Details for the oral presentation can be found below: Title:\u00a0Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants Session:\u00a0Pharmaceutical &hellip; Continue reading &quot;Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-30T15:33:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjQxOCM2ODM4NDcwIzUwMDA3NTM4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress\",\"datePublished\":\"2025-03-30T15:33:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/\"},\"wordCount\":271,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjQxOCM2ODM4NDcwIzUwMDA3NTM4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/\",\"name\":\"Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjQxOCM2ODM4NDcwIzUwMDA3NTM4MQ==\",\"datePublished\":\"2025-03-30T15:33:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjQxOCM2ODM4NDcwIzUwMDA3NTM4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjQxOCM2ODM4NDcwIzUwMDA3NTM4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/","og_locale":"en_US","og_type":"article","og_title":"Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - Market Newsdesk","og_description":"CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place March 29 to April 2, 2025 in Chicago, Illinois, U.S. Details for the oral presentation can be found below: Title:\u00a0Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants Session:\u00a0Pharmaceutical &hellip; Continue reading \"Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-30T15:33:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjQxOCM2ODM4NDcwIzUwMDA3NTM4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress","datePublished":"2025-03-30T15:33:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/"},"wordCount":271,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjQxOCM2ODM4NDcwIzUwMDA3NTM4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/","name":"Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjQxOCM2ODM4NDcwIzUwMDA3NTM4MQ==","datePublished":"2025-03-30T15:33:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjQxOCM2ODM4NDcwIzUwMDA3NTM4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjQxOCM2ODM4NDcwIzUwMDA3NTM4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-schizophrenia-at-2025-sirs-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=831326"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831326\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=831326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=831326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=831326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}